Giorgia Battipaglia

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 85 publications

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

The 2026 definition of ruxolitinib refractoriness in severe acute GVHD.

Journal: Bone marrow transplantation

Published: April 03, 2026

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Real-world approaches to preventing acute myeloid leukemia relapse after allogeneic transplantation: a national survey by GITMO (Gruppo Italiano Trapianto Midollo Osseo).

Journal: Bone marrow transplantation

Published: April 01, 2026

An Italian cartography of VEXAS-related thrombosis.

An Italian cartography of VEXAS-related thrombosis.

Journal: HemaSphere

Published: January 17, 2026

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Donor cell-derived haematological neoplasms after allogeneic haematopoietic cell transplantation: recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: The Lancet. Haematology

Published: January 12, 2026

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: December 04, 2025

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from the EBMT practice harmonisation and guidelines committee.

Journal: Bone marrow transplantation

Published: November 30, 2025

Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT.

Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT.

Journal: American journal of hematology

Published: October 10, 2025

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on 'real world' experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm.

Journal: Bone marrow transplantation

Published: September 05, 2025

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Trends in GVHD Epidemiology, Prophylaxis and Management: The Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare (GITMO) GVHD24 Study.

Journal: American journal of hematology

Published: August 22, 2025

Usage of rabbit anti-thymocyte / anti-T-lymphocyte globulins (ATG / ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Usage of rabbit anti-thymocyte / anti-T-lymphocyte globulins (ATG / ATLG) for hematological malignancies in allogeneic hematopoietic cell transplantation: Best practice recommendations from the EBMT Practice Harmonisation and Guidelines Committee.

Journal: Bone marrow transplantation

Published: August 06, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal

Published: July 29, 2025

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.

Journal: Bone marrow transplantation

Published: July 24, 2025

Showing 1-12 of 85

Last Updated: 09/26/2026